369 related articles for article (PubMed ID: 24280723)
1. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
[TBL] [Abstract][Full Text] [Related]
3. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
[TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
Tamminen K; Malm M; Vesikari T; Blazevic V
Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
[TBL] [Abstract][Full Text] [Related]
6. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
7. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
[TBL] [Abstract][Full Text] [Related]
8. Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.
Heinimäki S; Malm M; Vesikari T; Blazevic V
J Immunol Res; 2018; 2018():3487095. PubMed ID: 29682589
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
10. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
[TBL] [Abstract][Full Text] [Related]
11. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.
Jackson EM; Herbst-Kralovetz MM
PLoS One; 2012; 7(7):e41529. PubMed ID: 22855691
[TBL] [Abstract][Full Text] [Related]
12. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
[TBL] [Abstract][Full Text] [Related]
13. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.
Kim SH; Chen S; Jiang X; Green KY; Samal SK
J Virol; 2014 Sep; 88(17):9718-27. PubMed ID: 24920815
[TBL] [Abstract][Full Text] [Related]
15. Modular virus-like particles for sublingual vaccination against group A streptococcus.
Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
[TBL] [Abstract][Full Text] [Related]
16. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.
Tacket CO; Sztein MB; Losonsky GA; Wasserman SS; Estes MK
Clin Immunol; 2003 Sep; 108(3):241-7. PubMed ID: 14499247
[TBL] [Abstract][Full Text] [Related]
17. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.
Springer MJ; Ni Y; Finger-Baker I; Ball JP; Hahn J; DiMarco AV; Kobs D; Horne B; Talton JD; Cobb RR
Vaccine; 2016 Mar; 34(12):1452-8. PubMed ID: 26873053
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.
Ball JM; Hardy ME; Atmar RL; Conner ME; Estes MK
J Virol; 1998 Feb; 72(2):1345-53. PubMed ID: 9445035
[TBL] [Abstract][Full Text] [Related]
19. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
20. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.
El-Kamary SS; Pasetti MF; Mendelman PM; Frey SE; Bernstein DI; Treanor JJ; Ferreira J; Chen WH; Sublett R; Richardson C; Bargatze RF; Sztein MB; Tacket CO
J Infect Dis; 2010 Dec; 202(11):1649-58. PubMed ID: 20979455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
